Follow the volume. This is going back up any day when he give the proof. He can't go around saying he has a 3 year deal with T mobile. T mobile has shareholders who they look out for. I am sure T mobile would sue if Max was putting false info about T mobile all over the place. This is when you reload. Reload opportunity! Max knows what he is doing. Shaking the tree hard.

Big News coming any day. Been awhile. They are due

Best potential I seen since Kaly

https://backend.otcmarkets.com/otcapi/company/dns/news/document/38111/content

locked and loaded and ready for a PR.

314 million o/s on a trip stock about to be doing business with T Mobile. No brainer. Max Chen Li CEO of Saddle Ranch Media INC. Clearly has a solid game plan with a hard working determined CEO.. $$$WINNER$$$ $$$$SRMX$$$$$ Hold for dollars in 2022

https://www.bloomberg.com/profile/person/20981043

I wonder if this is the same Max Li? https://investorshub.advfn.com/uimage/uploads/2019/9/19/jigyu0.jpg

$$$$$$Winner-SRMX$$$$$$

Going Long on this one! https://backend.otcmarkets.com/otcapi/company/dns/news/document/38111/content

A chance at 3's is very realistic. 2.87 might be pushing it.

It's coming this week! Gonna get PAIDDDDDDDDDDDDDD

TGGI.01 with news!

I agree! Great Job gonna make a killing on this. This merger news is going to KICK ARSE!

Quality site, great grow ops, looks like they are doing things the right way. $$$GBHPF$$$ https://www.globalhempgroup.com/

https://www.theadvocate.com/baton_rouge/news/business/article_c97abdcc-119f-11e8-9a86-e393c4bdf663.html

Press Release: GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation
Today 12:34 PM ET (Dow Jones)Print


GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation
PR Newswire
LAS VEGAS, Sept. 17, 2019
LAS VEGAS, Sept. 17, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. The stake will be purchased by Wellcana Plus LLC, affiliated through its managers with the group which holds the other 50% of the Louisiana operations. Expected to close by the end of October 2019, the sale is for $16 million to GB Sciences, $7 million in cash at closing, $1 million in cash within 60 days of closing, and the remaining $8 million as an earn out. The actual proceeds realized through the earn out and the timing of those proceeds will depend upon the profitability of the Louisiana operations.
The sale will greatly reduce the current and future burn rate of the Company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the US Food and Drug Administration to ensure quality control in the manufacture of pharmaceuticals, dietary supplements and natural health products among other substances, at its Las Vegas, Nevada location. GB Sciences also will continue to develop its clinical cannabis formulations for which the Company has filed numerous patents, progressing the research towards clinical trials and first-in-human pilot studies.
GB Sciences and GB Sciences Louisiana will endeavor to collaborate on research and clinical trial opportunities, and the Company will grant GB Sciences Louisiana the opportunity to license the Company's proprietary formulations for use in research and final formulations upon mutually agreeable terms.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements

$$$$$$$ GBLX sold $32 Million$$$$

Maybe they have news all the time because they got the terminator behind their product. If Arnold is down with Pura, it's probably quality.

Proof?

Correction: HOLIDAY ISLAND ACQUIRES https://t.co/L9KVVed6oQ TO OFFICIALLY ENTER THE $20 BILLION CBD MARKET AND UPDATES ON FUTURE MERGER $HIHI #cbd #blockchainproject #realestateinvesting #investing #money #growhemp

— HiHi_OTC (@HihiOtc) September 12, 2019

It Doesn’t Look like ACB Stock Is Going Anywhere This Year
ACB stock won't get traction any time soon
By Tom Taulli, InvestorPlace Writer & IPO Playbook Editor Sep 17, 2019, 8:10 am EDT
Aurora Cannabis (NYSE:ACB) joined companies like Tilray (NASDAQ:TLRY), Canopy Growth (NYSE:CGC) and Cronos (NASDAQ:CRON) when its recent earnings report sent ACB stock on a 9% tumble.

Source: Shutterstock
Because of this, there has been a wide-scale bear move. The fact is that investors have been too optimistic about the growth prospects from Canada. There have also been issues with supply chains in the country as well as black market activities.
So when may things change? It may take a while.
But even before this, the ACB stock price had been under increasing pressure. Since March, the shares have gone from $10 to $5.70.
Now, as for the fiscal fourth-quarter earnings report for the company, there was still lots of growth. On a quarter-over-quarter basis, revenues jumped by 52%. There was also an annual 72% ramp.
Yet Wall Street wanted much more. ACB reported C$98.9 million on the top-line while the consensus was calling for C$103 million. Note that before this the company had tempered its annual guidance.
Something else about the earnings report that likely weighed on Aurora Cannabis stock was the softness in the global business. Consider that there was only a 12% increase in the medical segment in Europe to C$4.5 million.
InvestorPlace.com’s Josh Enomoto summed things up as follows:
“The cannabis market has stepped out of the honeymoon phase and into the ‘show me’ phase. In other words, investors are tired of hearing bedtime stories. Instead, they want some evidence that these tales are based on facts.”
Bad News for ACB Stock
Aurora Cannabis stock got hit again this week, off about 4%. The reason: negative commentary from Stifel Nicolaus analyst Andrew Carter. Primarily because of the earnings report, especially with the sluggishness in foreign markets, he slapped a “sell” rating on the shares. He lowered his price target from C$7 to C$5.
He also thinks the terrible sentiment in the cannabis sector will make it more difficult for Aurora Cannabis to raise more money. No doubt, this could mean that any equity offering could see substantial dilution – which could mean even further deterioration of the stock price.
An Upside for ACB Stock
Despite all the bad news, there remain silver linings. Aurora Cannabis has the advantage of scale and a global infrastructure (there are 15 production facilities, with sales and operations in 25 countries). For example, during the quarter the company produced over 29,000 kilograms, compared to 15,590 for the prior quarter.
Another advantage for Aurora Cannabis stock is that it has Nelson Peltz as a strategic advisor. He is a top activist investor who has extensive experience with consumer goods companies like Procter & Gamble (NYSE:PG), Mondelez (NASDAQ:MDLZ), and Wendy’s (NASDAQ:WEN). Peltz should be invaluable in providing high-level contacts and funding resources.
And finally, there is the catalyst of “Legalization 2.0.” This refers to when Canada will legalize the sale of cannabis edibles, beverages and vaping products. The law will require a 60-day permit process, after which sales will be allowed.
This should help to boost revenues. However, in light of the concerns with cannabis companies right now, there may not much action with Aurora Cannabis stock until next year. So for now, there is probably no rush to make a buy.
Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.
5 TINY CRYPTOCURRENCIES THAT COULD TURN $500 INTO $5 MILLION

5 Tiny Cryptocurrencies That Could Turn $500 Into $5 Million
Right now, over 100 billionaires and wealthy investors are in a buying frenzy, preparing for a rare crypto market phenomenon we won’t see again until 2024. The last time it occurred, you could’ve turned $500 into as much as $5 million… in just 10 months.
On SEPTEMBER 18, Teeka Tiwari, the go-to analyst in the crypto space, will explain what this little-known event is... why it’s 100% guaranteed to happen... and share details on the 5 tiny coins insiders are buying now.
Plus, he’s revealing the name of his #1 Crypto Pick. All FREE, during the “5 Coins to $5 Million” webinar — LIVE on September 18.

New Report Claims Latin American Cannabis Markets Show No Signs Of Near-Term Development
Today 9:00 AM ET (Benzinga)Print

Market research and cannabis consultancy company Brightfield Group on Tuesday released a report analyzing the current state of the Latin American cannabis market. The report focuses on looking at each country’s legislation, to assess their potential consumer markets.
Too Green For The Green Rush?
The report analyses the situation of the cannabis industry in Chile, Mexico, Colombia, Brazil, Argentina, Peru and Uruguay. It’s important to point out that these countries only account for seven out of the 20 countries that make up the region.
A region overview by the Brightfield Group states that, although many Latin American countries are developing policies that will eventually lead to legal marijuana markets, the business opportunities behind these markets are limited. According to the study, the results derived from today’s authorized medical and recreational marijuana markets are “unlikely to provide significant market potential in the near term.''
Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.
CBD, King In The Region
According to the report’s projections, CBD is expected to become the most important cannabis segment by far, reaching $448 million by 2023, with Mexico accounting for over half of that market. Medical marijuana is expected at $109 million by that same year and recreational projections show no growth from today’s scenario.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
Big Expectations For Cultivation And Export Potential
Although consumer markets in Latin America cannot compete with the U.S. or European demand, the region shows a promising potential as an exporter of cannabis products, thanks to good weather conditions for marijuana growth, and low farming costs.
Several big weed companies like Canopy Growth (NYSE: CGC), Aurora (NYSE: ACB), Aphira (NYSE: APHA), Tilray (NASDAQ: TLRY) and Khiron (OTC: KHRNF) have already made investments in Latin American soil, and some have already seen their first crops.
Regulation, however, has not yet allowed for big exports to leave their homeland and reach international shelves.
A ‘Wait And See’ Case
According to the report, low average household incomes, patients’ freedom to grow their own cannabis, and strictly regulated medical markets are placing Latin America away from world-class markets like Canada, some US states and some European countries.
However, educational efforts from advocacy organizations and international investors are shaping public opinion positively for cannabis, generating demand on medical cannabis.
Although the report offers a sensible overview of the region’s panorama, it lacks certain traits shared by academic-level market studies. This means that, while its projections might be accurate, it’s not recommended to take them for granted, since the report offers no evidence to the reliability of its sources or method used in projecting its results.
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

UPDATE: Aurora Cannabis stock sinks after analyst says it's time to 'sell'
Today 3:18 PM ET (MarketWatch)
Share
Print


By Tomi Kilgore, MarketWatch
Stifel Nicolaus turns bearish, slashes price target in wake of 'bad' quarterly results
Aurora Cannabis Inc. shares tumbled Monday after Stifel Nicolaus analyst Andrew Carter told clients it was time to sell, noting that though the headlines of the Canada-based cannabis company's latest quarterly report were bad, the details of the results were even worse.
Carter downgraded Aurora's stock (http://www.marketwatch.com/story/aurora-cannabis-stock-falls-after-stifel-says-sell-slashes-price-target-2019-09-16) to sell, a little more than three months after initiating coverage with a hold rating (http://www.marketwatch.com/story/cannabis-sector-resumes-selloff-as-investors-shrug-off-bullish-canopy-note-2019-06-06). He slashed his price target on the Canada-listed stock to C$5, which is 31% below current levels from C$7.
The Canada-listed shares(ACB.T) shed 7.4%, while the U.S.-listed shares(ACB.T) slumped 7.5% in active morning trading. Volume in the U.S.-listed stock topped 29.3 million shares at around 3:15 p.m. Eastern, compared with the full-day average of about 13.3 million shares, according to FactSet data.
Aurora reported last week a wider-than-expected fiscal fourth-quarter loss and revenue that missed lowered expectations, sending the stock tumbling over 9% last Thursday. See Cannabis Watch (http://www.marketwatch.com/search).
Don't miss: Aurora Cannabis stock drops after earnings, as pot sales miss revised target (http://www.marketwatch.com/story/aurora-cannabis-stock-drops-after-earnings-miss-2019-09-11).
Stifel's Carter helped weigh on the stock immediately after the results by saying he believed the stock would remain under pressure given expectations that it would need to access the capital markets for a "significant ask (http://www.marketwatch.com/story/aurora-cannabis-stock-to-be-pressured-by-need-for-significant-capital-raise-analyst-says-2019-09-12)"; to fund its aggressive growth plans.
But Carter said on Monday that Aurora's efforts to tap the capital markets will be "challenged" given the "overwhelmingly negative investor sentiment" towards the cannabis sector, damaged credibility and limited near-term catalysts to drive investor enthusiasm.
Also read: Cannabis companies are having a horrible summer as scandals mount and stocks slide (http://www.marketwatch.com/story/cannabis-companies-are-having-a-horrible-summer-as-scandals-mount-and-stocks-slide-2019-07-25).
'The headlines were bad, the details were worse'
In a note titled "The headlines were bad, the details were worse: Downgrade to sell" on Monday, Carter said the fourth-quarter results point to a "less robust in-market performance" and difficulty to continue positioning for the larger global opportunity.
"Our outlook suggests significant downside potential for the shares of Aurora over the near term, given it will be difficult for the company to continue positioning for the larger global opportunity within the confines of significant financing risk that could challenge the company's ability to fully embrace the level of investment needed to be a leader not only in the global cannabis category but also in Canada," Carter wrote.
He said he believes the company will remain challenged until it can attract an investment from a consumer partner.
Carter's call for a consumer partner comes after Corona-beer parent Constellation Brands Inc(STZ) made a $4 billion investment last year in Canopy Growth Corp (http://www.marketwatch.com/story/canopy-growth-is-at-the-top-of-the-food-chain-as-canada-gears-up-for-legal-weed-2018-08-29).(WEED.T) (WEED.T) , which led to the ousting of high-profile co-Chief Executive Bruce Linton (http://www.marketwatch.com/story/canopy-growth-stuns-with-news-that-co-ceo-bruce-linton-is-stepping-down-2019-07-03), and after cigarette seller Altria Group Inc.(MO) said it would pay the equivalent of $1.8 billion (http://www.marketwatch.com/story/cannabis-stock-cronos-soars-24-as-altria-takes-major-stake-2018-12-07) for a 45% stake in Cronos Corp.(CRON.T) (CRON.T)
See related: Canopy Growth's remaining CEO talks about pot company's shake-up, and the search for his replacement (http://www.marketwatch.com/story/canopy-growths-remaining-ceo-talks-about-pot-companys-shake-up-and-the-search-for-his-replacement-2019-09-09).
Carter said Aurora will likely have trouble competing with rivals Canopy Growth and Cronos in the global cannabis market until it can tout a partnership with a well-established and vested consumer partner. While those partnerships helped provide significant capital "de-risking" for Canopy Growth and Cronos, the risk has increased for Aurora given the recent volatility in the equity markets and uncertainty over Aurora's willingness and ability to attract a partner.
"Aurora has given mixed commentary on pursuing partnerships, but we believe the company will be required to continue pursuing an independent path with global consumer companies likely taking a wait-and-see approach to the sector with less incentive to partner with a Canadian L.P.," Carter wrote.
Aurora's stock has tumbled 27% over the past three months, while the ETFMG Alternative Harvest exchange-traded fund(MJ) has slumped 21% and the S&P 500 index has gained 3.9%.
-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires
September 16, 2019 15:18 ET (19:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.

I seen GBLX fall through on a couple big deals in the past.

All this volume and still at the same opening price. Looks like accumulation to me.

We are moving very fast to acquire Powell’s Hardware building which includes a parking lot. We are in talks with a couple of merger candidates who are very interested in rolling in their private company under $HIHI. Full details will be released via a press release.


Good to see multiple Merger candidates very interested into merging into $$$$HIHI$$$$

Aurora Cannabis stock price target cut to C$5 from C$7 at Stifel Nicolaus
Today 7:18 AM ET (MarketWatch)
Share
Print



(END) Dow Jones Newswires
September 16, 2019 07:18 ET (11:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.

HIHI

Looks like gbhpf will be trading in the .04 - .05 channel by next week

MedMen started at underperform with $1.50 stock price target at Cowen

I don't think HIHI can go much lower. HIHI is trading at lower levels than thru out the year. To much positive news. I am grabbing more every time this goes down if it does go down anymore.

Can't wait for the ride to pennyland! hold those HIHI shares, block out the noise, HIHI will be flying When the R/M news breaks next week. $$$$HIHI$$$$$ SLAP THE ASK. HIHI is a big money play.

Stocks have 'sufficient tailwind' to climb higher -- keep buying: Credit Suisse
Today 9:00 AM ET (MarketWatch)
Share
Print


By MarketWatch
MARKETWATCH FRONT PAGE (http://www.marketwatch.com)
Our call of the day is from Credit Suisse's global equity strategist Michael Strobaek who is not fazed by the S&P 500's 20% gain this year. He says it's time to buy more stocks. See full story (http://www.marketwatch.com/story/stocks-have-sufficient-tailwind-to-climb-higher-keep-buying-credit-suisse-2019-09-13).
He moved to America at 20 with just $400, and retired at 53 to sail the world -- here's how he did it
Want to retire early? Atlanta residents Mark Erdos and his wife Cindy have some sage advice. See full story (http://www.marketwatch.com/story/he-moved-to-america-at-20-with-just-400-and-retired-at-53-to-sail-the-world-heres-how-he-did-it-2019-09-13).
Stop pushing poor people to save more for retirement
Here's why it doesn't always make financial sense for them. See full story (http://www.marketwatch.com/story/stop-pushing-poor-people-to-save-more-for-retirement-2019-09-12).
This budget shows how a $350,000 salary barely qualifies as middle class
Most Americans would probably have a hard time wrapping their heads around a $350,000 salary. The thing is, that kind of income, while relatively huge, is barely enough, according to Financial Samurai blogger Sam Dogen, for a family to lead a comfortable life in coastal counties -- where almost half of the nation's population calls home. See full story (http://www.marketwatch.com/story/this-budget-shows-how-a-350000-salary-barely-qualifies-as-middle-class-2019-09-11).
Cannabis companies have secret formulas to determine when the U.S. may allow pot sales
The two largest pot companies in the world have developed secret formulas that predicts U.S. federal and state cannabis legalization. See full story (http://www.marketwatch.com/story/cannabis-companies-have-secret-formulas-to-determine-when-the-us-may-allow-pot-sales-2019-09-12).
MARKETWATCH PERSONAL FINANCE (http://www.marketwatch.com/personal-finance/)
Ditching credit cards for facial recognition removes the last physical barrier between our bodies and Corporate America. See full story (http://www.marketwatch.com/story/the-technology-that-should-finally-make-your-wallet-obsolete-2019-09-06).
-MarketWatch; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires
September 13, 2019 09:00 ET (13:00 GMT)

I know of many stocks trading near or over a penny with a Billion O/S+ that has less going on. A .0006 stock with a CBD website generating 50k to 100k a month with no dilutive notes, debt, and a R/M about to happen. This is going to pennyland!

Slap the ask. No dilution. R/M news next week. Acquisition of CBD247Store.com making 50- $100 grand every month. I aint 't selling. I doubled my position.

Good call Chicago-Paul.

176 mil bid 8.9 mil ask

2 more new tweets. CBD247.com Revenue between $50,000-100,000 a month https://twitter.com/HihiOtc

Check out their website. They are all about community development.